NEW YORK , June 10, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX) , a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic...
– Late-Breaking Poster Introduces New Unified Statistical Analyses for Assessing Confirmed Disability Changes for Trials in Progressive Multiple Sclerosis –
– Proven Leader with Deep Multiple Sclerosis Expertise; Played Key Role in the Launch of Ocrevus ® –
– More Than 30 Years of Leadership Experience Across Biopharmaceutical Commercialization –
– Appointed Globally Renowned Biopharmaceutical Executive and Neurology Drug Developer, Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer –
– Proven Leader in Neurology Drug Development, Including for Several Approved Multiple Sclerosis Therapies –
NEW YORK , April 23, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX) , a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic...
NEW YORK , April 9, 2026 /PRNewswire/ -- Immunic , Inc.  (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases,...
NEW YORK , April 1, 2026 /PRNewswire/ -- Immunic , Inc. Â (Nasdaq: IMUX) , Â a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic...